Chargement en cours...
Denosumab in Postmenopausal Osteoporosis: What the Clinician Needs to Know
Denosumab is a subcutaneously (SC) administered investigational fully human monoclonal antibody to receptor activator of nuclear factor-kB ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the principal mediator of osteoclastic bone resorption. RANKL stimulates the format...
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
SAGE Publications
2009
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3382669/ https://ncbi.nlm.nih.gov/pubmed/22870424 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1759720X09343221 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|